LinkDoc Technology
Chinese oncology real-world-data firm linking hospitals for cancer research analytics.
On the record
Checkpoint: Deadline for any confirmed capital event, listing filing, or product disclosure from LinkDoc
The call
LinkDoc has had no confirmed funding, product news, or financial disclosure since 2021 while its listed peer Yidu Tech ships AI tools and turns a profit.
LinkDoc collects real-world medical information from hospitals in China, especially for cancer patients, and sells access to pharmaceutical companies and researchers. The company has genuine advantages because Chinese hospitals require special permission and long-term trust to share patient data, which new competitors cannot quickly build. However, LinkDoc has not raised money since early 2021, its planned New York stock listing was cancelled, it has announced no business activity in recent years, and its rival Yidu Tech is already public, making money, and using new AI tools from companies like Alibaba and Baidu to do the same work faster. The one thing that could change everything is if LinkDoc announces new funding or a major customer deal by mid-2026, proving the company is still operating and has a real path forward.
Why
01
AI pressure: Yidu Tech AI-native platform, plus DeepSeek and Alibaba Cloud medical-NLP models. Rival Yidu Tech now runs an AI platform on 9B records while frontier LLMs commoditize the NLP curation LinkDoc used to sell. Could AI do the core job? Only partly.
02
Bigger players: Alibaba Health Information Technology. Alibaba is both an investor and a competing internet-hospital and pharmacy data channel, squeezing LinkDoc from two sides at once. Could a giant copy it? Probably.
03
What protects it. Years of hospital ethics approvals and direct clinical relationships that a new entrant cannot fast-track.
What would change this call
LinkDoc files for HK/A-share listing or discloses new funding by Q2 2026. Would show the company regained a capital path after its 2021 IPO withdrawal.
LinkDoc publishes any 2024-2026 product, AI, or revenue disclosure. Would show commercial continuity instead of prolonged public silence.
Yidu Tech reports another year of double-digit revenue growth or new hospital contracts. Would widen the gap with LinkDoc in the same regulated data niche.
LinkDoc publishes any 2024-2026 product, AI, or revenue disclosure. Would show commercial continuity instead of prolonged public silence.
Yidu Tech reports another year of double-digit revenue growth or new hospital contracts. Would widen the gap with LinkDoc in the same regulated data niche.
Key numbers
- Withdrew $200M+ Nasdaq IPO filing
- Yidu Tech FY2026 revenue RMB 819.3M, up 14.6%
- Claimed 500+ hospital partnerships in 2021 filing
Named risks
- No confirmed capital raised since March 2021 despite a failed $200M plus IPO and reported cash crunch warning.
- No public product, funding, or financial disclosure found for 2022 to 2026, obscuring current operating status.
- Direct peer Yidu Tech is listed, profitable, and publicly marketing AI deployment, eroding LinkDoc's competitive narrative.
- Core NLP data-curation offering exposed to commoditization by frontier and vertical medical AI models.
- Headcount estimates conflict by orders of magnitude (81 vs 1,000 to 5,000), signaling absence of reliable primary disclosure.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Yidu Tech | losing to | Yidu Tech listed, profitable with RMB 72.7M net income and 14.6% revenue growth as of 2026-06-30; LinkDoc undisclosed since 2022 |
| Alibaba Health Information Technology | contesting | Alibaba Health is both a strategic investor in LinkDoc and a broader competitor in internet-hospital and pharmacy channels |
| Baidu, Alibaba Cloud, DeepSeek (medical NLP) | gaining on | Frontier and vertical medical NLP tools threaten to commoditize LinkDoc's core EMR curation layer as of 2026 |
| Taimei Technology | contesting | HKEX-listed clinical trial SaaS peer (MobileMD) operating in adjacent China healthcare data space |
Questions people ask
- Is LinkDoc Technology still operating in 2026?
- No confirmed activity has surfaced since LinkDoc withdrew its Nasdaq IPO filing on April 11, 2022. No funding round, product launch, or financial disclosure has been verified for 2023 through mid 2026, leaving its current operating status unconfirmed despite continued academic citations of its oncology data platform.
- Did LinkDoc Technology ever go public?
- No. LinkDoc filed for a Nasdaq IPO seeking up to $200 to 211 million in June 2021, postponed pricing on July 8, 2021 amid Beijing's offshore listing crackdown, and formally withdrew its SEC filing on April 11, 2022, per Renaissance Capital. No Hong Kong or A share listing has been confirmed since.
- How does LinkDoc compare to its rival Yidu Tech?
- Yidu Tech, LinkDoc's closest peer, is listed on HKEX and reported RMB 819.3 million revenue (up 14.6% year over year) with a swing to RMB 72.7 million net profit for the year ended March 31, 2026, per its HKEX filing. LinkDoc has disclosed no comparable financials since its 2021 IPO prospectus.
- Could AI replace LinkDoc Technology's core business?
- LinkDoc's NLP based curation of unstructured medical records into structured oncology data is exposed to commoditization by general purpose and medical NLP models from firms like Baidu and Alibaba Cloud. However, its reported network of roughly 500 hospital partnerships and regulatory data access relationships, if maintained, are harder for AI alone to replicate.
- Is it risky to join LinkDoc Technology as an employee in 2026?
- Headcount estimates for LinkDoc range wildly, from 81 employees per one aggregator dated April 2022 to a 1,000 to 5,000 employee band from another, with no primary correction in over four years. Combined with no confirmed funding since March 2021 and a failed IPO, joining carries significant disclosed uncertainty.
- Who owns LinkDoc Technology?
- LinkDoc is privately held, structured through a Cayman Islands holding company with a VIE arrangement into a Beijing operating entity. Founder and CEO Tianze Zhang held about 19.7% at the time of the 2021 IPO filing; strategic investors reportedly included Alibaba Health, Temasek's Esta Investments, and NEA.
Timeline
- 2022-04-11LinkDoc formally withdraws its $200M Nasdaq IPO filing with the SEC
- 2022LinkDoc-affiliated researcher co-authors paper on CDISC data standards for real-world data
- 2021-09Hong Kong media report says LinkDoc seeking ~$300M privately after IPO withdrawal
- 2021-07-12Reports warn LinkDoc faces possible cash crunch after IPO proceeds never arrived
- 2021-07-08LinkDoc becomes first Chinese firm to shelve US IPO amid Beijing offshore listing crackdown
- 2021-06LinkDoc files for Nasdaq IPO seeking up to $200 to 211 million under ticker LDOC
- 2021-03Last confirmed LinkDoc funding round, a strategic minority investment
- 2018-07-06LinkDoc raises $151M in Series D funding round
Revision history
30 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Chinese health data firm LinkDoc Technology officially withdraws $200 million US IPO (2022-04-11)
- LinkDoc becomes first Chinese firm to shelve US IPO after Beijing crackdown (2021-07-09)
- Medical Big Data Firm LinkDoc Cancels U.S. Listing Plan (2025-10-08)
- LinkDoc Technology Limited (2022-04-11)
- How Does LinkDoc Technology Company Work? (2025-07-11)
- Revenue, Competitors, Alternatives (2022-04-12)
- LinkDoc - Overview, News & Similar companies (2026-07-24)
- Yidu Tech Annual Results Announcement FY2026 (2026-06-30)
- Yidu Tech Interim Results Announcement (2025-11-27)
- Use of CDISC Standards for Real-world Data
- RWD48 Identification and Assessment of Real-World Oncology Data in China (2023-12-24)
- Medical Data Collector LinkDoc Could Face Cash Crunch After IPO Withdrawal (2021-07-12)